Chroman derivatives.
Patent Information
- Application Number
- MYPI1999005404
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 1998-12-17
- Filing Date
- 1999-12-13
- Publication Date
- 2000-06-17
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for novel intermediates in the synthesis of medicinal compounds that act on the central nervous system, which existing technologies have not adequately addressed.
Chroman derivatives of specific formulas, along with their salts, enantiomers, and hydrates, are developed using hydrogenation processes with enantiomerically enriched catalysts, particularly transition metal complexes, to produce compounds that can serve as intermediates for medicaments.
These chroman derivatives effectively function as intermediates in the synthesis of medicaments with central nervous system activity, leveraging enantiomerically enriched catalysts to enhance the efficiency and specificity of the hydrogenation and reduction processes.
Abstract
Description
Chroman derivativesThe invention relates to chroman derivatives of the formula Iin whichR1is acyl having 1-6 C atoms, -CO-R5or an amino protective group,R2is H or alkyl having 1-6 C atoms,R3, R4in each case independently of one another are H, alkyl having 1-6 C atoms, CN, Hal or COOR2,R5is phenyl which is unsubstituted or mono- or disubstituted by alkyl having 1-6 C atoms, OR2or Hal,X is H,H or 0,Hal is F, Cl, Br or I, and their salts.The invention also relates to the optically active forms, the racemates, the enantiomers and also the hydrates and solvates, e.g. alcoholates, of these compounds .Similar compounds are disclosed in EP 0 707 007.The invention was based on the object of finding novel compounds which can be used, in particular, as intermediates in the synthesis of medicaments.It has been found that the compounds of the formula I and their salts are important intermediates for the preparation of medicaments, in particular of those which show, for example, actions on the central nervous system.The invention relates to the chroman derivatives of the formula I and their salts.Above and below, the radicals R1, R2, R3, R4, Rsand X have the meanings indicated in the formulae I and II, if not expressly stated otherwise.In the above formulae, alkyl has 1 to 6, preferably 1, 2, 3 or 4, C atoms. Alkyl is preferably methyl or ethyl, furthermore propyl, isopropyl, in addition also butyl, isobutyl, sec-butyl or tert-butyl. Acyl has 1 to 6, preferably 1, 2, 3 or 4, C atoms. Acyl is in particular acetyl, propionyl or butyryl.R2is preferably' H, in addition also methyl, ethyl or propyl.R3and R4are preferably H.Rbis preferably, for example, phenyl, ο-, m- or p-tolyl, ο-, m- or p - hydroxyphenyl, ο-, m- or p-methoxyphenyl, ο-, m- or p-fluorophenyl. The radical R1is acyl, -CO-R5or else an amino protective group which is known per se; acetyl is particularly preferred .The expression amino protective group is generally known and relates to groups which are suitable for protecting (for blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other positions in the molecule. Typical groups of this type are, in particular, unsubstituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their nature and size is otherwise uncritical; however, those having 1-20, in particular 1-8, C atoms are preferred. The expression acyl group is to be interpreted in the widest sense in connection with the present process and the present compounds. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids and also, in- , 3 particular, alkoxycarbonyl , aryloxycarbonyl and especially aralkoxycarbonyl groups. Examples of acyl groups of this type are alkanoyl such as acetyl propionyl, butyryl; aralkanoyl such as phenylacetyl;aroyl such as benzoyl or toluyl; aryloxyalkanoyl such as phenoxyacetyl; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichlo^oethoxycarbonyl, BOC (tert-butoxycarbonyl) ,- iodoethoxycarbonyl; aralkyl oxycarbonyl such as CBZ (carbobenzoxycarbonyl, also called Z)4-methoxybenzyloxycarbonyl, FMOC (9-fluorenylmethoxycarbonyl); arylsulfonyl such as Mtr (4-methoxy2,3,6-trimethylpheny1sulfony1) . Preferred amino protective groups are BOC and Mtr, in addition CBZ or 15 FMOC.The compounds of the foimula I can have one or more chiral centres and therefore occur in various stereoisomeric forms. The formula 1 includes all these forms.The invention furthermore relates to a process for the preparation of chroman derivatives of the formula 1and also of their salts, in which X is O, characterized in that a compound of the formula IIPI 99005404 in whichR1is acyl having 1-6 carbon atoms, -CO-R5, phenylacetyl, phenoxyacetyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, 2-iodoethoxycarbonyl, carbobenzoxy-carbonyl, 4-methoxybenzyloxycarbonyl, 9fluorenylmethoxycarbonyl or 4-methoxy-2,3,6-trimethyl-phenylsulfonyl, R2is H or alkyl having 1-6 carbon atoms, R3and R4are each, independently of one another, H, alkyl having 1 -6 carbon atoms, CN, Hal or COOR2, and X is O, is hydrogenated with the aid of an enantiomerical ly enriched catalyst.The invention also relates to a process for the preparation of chroman derivatives of the formula 1 and also of their salts, in whichX is H,H, characterized in that a compound of the formula IIR2in whichR1is acyl having 1-6 carbon atoms, -CO-R5, phenylacetyl, phenoxy acetyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, 2-iodoethoxycarbonyl, carbobenzoxy-carbonyl, 4-methoxybenzyloxycarbonyl, 9fluorenylmethoxycarbonyl or 4-methoxy-2,3,6-trimethyl-phenylsulfonyl. R2is H or alkyl having 1-6 carbon atoms, R3and R4are each, independently of one another, H, alkyl having 1-6 carbon atoms, CN, Hal or COOR2, and X is O, is hydrogenated with the aid of an enantiomerically enriched catalyst, and then reduced in the customary manner.PI99005404In particular, it has been found that (2-acetylaminomethyl)chromen-4-one can be hydrogenated using various enantiomerically pure rhodium-diphosphane complexes to give enantiomerically enriched (2-acetylaminomethyl)chroman-4-one .The invention also relates to a process for the preparation of chroman derivatives of the formula I, characterized in that the enantiomerically enriched catalyst is a transition metal complex.Particularly preferably, the catalyst is a transition metal complex comprising a metal selected from the group rhodium, iridium, ruthenium and palladium.The invention furthermore relates to a process for the preparation of chroman derivatives of the formula I, characterized in that the catalyst is a transition metal complex in which the transition metal is complexed with a chiral diphosphane ligand.The ligands below may be mentioned by way of example:PI 99005404 (S)-EtDuphos:BINAP :(S,S)-Chiraphos:PPh, PPh, (S,S)-DIOP:PPh2PPh, (S,S) -Skewphos (BDPP) .· (S,S)-BPPM:PPh2Ph2PPI 99005404 (R,R)-Norphos :(S,R)-BPPFOH:Depending on the choice of the (R) or (S) enantiomer of the ligand in the catalyst, the (R) or (S) enantiomer is obtained in an excess.Precursors used for the chiral ligands are compounds such as, for example, Rh(COD)2OTf (rhodiumcyclooctadiene triflate) , [Rh(COD)Cl]2, Rh (COD)2BF4, [Ir (COD) Cl],, Ir(COD)2BF4or [Ru (COD) Cl2]x.The compounds or the formula I and also the starting substances for their preparation are otherwise prepared by methods known per se, such as are described in the literature (e.g. in the standard works such as HoubenWeyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), mainly under reaction conditions which are known and suitable for the reactions mentioned. Use can also be made in this case of variants which are known per se, but not mentioned here in greater detail.PI 99005404If desired, the starting substances can also be formed in situ such that they are not isolated from the reaction mixture, but immediately reacted further to give the compounds of the formula I.The compounds of the formula II are known in some cases; the unknown compounds can easily be prepared analogously to the known compounds.The conversion of a compound of the formula II in which X is 0 into a compound of the formula I in which X is O is carried out according to the invention using hydrogen gas with the aid of an enantiomerically enriched catalyst in an inert solvent such as, for example, methanol or ethanol.Suitable inert solvents are furthermore, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane , carbon tetrachloride, chloroform or dichloromethane; alcohols such as isopropanol, n-propanol, n-butanol or tertbutanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones such as acetone or butanone; amides such as acetamide, dimethylacetamide or dimethyl formamide (DMF) ; nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); carbon disulfide; nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate, and optionally also mixtures of the solvents mentioned with one another or mixtures with water.The reaction time hydrogenation, depending between a few minutes of the enant ioselect ive on the conditions used, is and 14 days; the reactionPI 99005404 temperature is between 0 and 150°, normally between 20 and 130°.Customarily, the catalyst / substrate ratio is between 1:2000 and 1:50, particularly preferably 1:1000 and 5 1:100. The reaction time is then, for example, between and 20 hours. The hydrogenation is carried out under 0.1-20 MPa (1-200 bar) of hydrogen, preferably at 0.3-10 MPa (3-100 bar).The. conversion of a compound of the formula II in which X is 0 into a compound of the formula I in which X is H,H is carried out according to the invention using hydrogen gas with the aid of an enantiomerically enriched catalyst in an inert solvent such as methanol or ethanol, such as described above, followed by a conversion of the 4-oxo group into a methylene group according to known conditions. The reduction is preferably carried . out using hydrogen gas under transition metal catalysis (for example by hydrogenation on Raney nickel or Pd-carbon in an inert solvent such as methanol or ethanol 1The conversion of compounds of the formula I in which R’, R4is COOalkyl into compounds of the formula I in which R3, R4is COOH is carried out, for example, using 25 NaOH or KOH in water, water-THF or water - dioxane at temperatures between 0 and 100°.lhe removal of e; radical R1from a compound of the formula i is carried out - depending on the protective 30 group used - for example using strong acids, expediently using TFA (trifluoroacetic acid) or perchloric acid, but also using other strong inorcanic acids such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids such as trichloroacetic 35 acid or sulfonic acids such as benzene- or p-toluenesulfonic acid. The presence of an additional inert solvent is possible, but not alwavs necessity. Suitable inert solvents are preferably organic solvents, for example carboxylic acids such as aceticPI 990054 04 scid, others such ss tetrahydroiuran or dioxane, amices such as dimethyl formamide, halogenated hydrocarbons such as dichloromethane, in addition also alcohols such as methanol, ethanol or isopropanol and also water. In 5 addition, mixtures of the abovementioned solvents are possible. TFA is preferably used in an excess without addition of a further solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in the rat_o 9: 1. The reaction temperatures are .10 expediently between approximately 0 and approximately 50°; the reaction is preferably carried out between 15 and 30°.The BOC group is preferably removed using TFA in 15 dichloromethane or using approximately 3 to 5 N hydrochloric acid in dioxane at 15-30°.The removal of the acetyl group is carried out according to customary methods (P.J. Kocienski , Protecting Groups, Georg Thieme Verlag, Stuttgart, 20 1994).Hydrogenolyt.ically removable protective orouDS (e.o. CBZ or benzyl) can be removed, for example, by treating with hydrogen in the presence of a catalyst (e.g. of a 25 noble metal catalyst such as palladium, expediently on a support such as carbon). Suitable solvents in this case are those indicated above, m particular, for example, alcohols such as methanol or ethanol or amides such as DMF. As a rule, the hydrogenolysis is carried 30 out at temperatures between approximately 0 and 100° and pressures between approximately 0.1 and 20 MPa (1 and 200 bar), preferably at 20-30° and 0.1-1.0 MPa (1-10 bar).A base of the formula I can be converted into the associated acid addition salt using an acid, for 35 example by reaction of equivalent amounts of the base and or the acid m an inert solvent such as ethanol ana subsequent evaporation. For this reaction, suitable c c d s de particularly* those v? h i c h vield physiologically acceptable salts. Thus inorganic acidsPl 99005404 can be used, e.g. sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, in addition organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g. formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, P-toluenesulfonic acid, naphthalenemono- and disulfonic acids and laurylsulfuric acid. Salts with physiologically unacceptable acids, e.g. picrates, can be used for the isolation and / or purification of the compounds of the formula I .On the other hand, compounds of the formula I can be converted into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, using bases (e.g. sodium or potassium hydroxide or carbonate), or into the corresponding ammonium salts.The invention furthermore compounds of the formula synthesis of medicaments, described, for example,The invention accordingly use of the compounds of relates to the use of the I as intermediates for the Appropriate medicaments are in EP 0 707 007.relates in particular to the the formula Iin the synthesis o (R) -2- [5- (4 - fluorophenyl) - 3-pyridylmethylaminomethyl]chroman and its salts, characterized in thata) a comnound of the formula ITXin whichR1is acyl having 1-6 carbon atoms, -CO-R5, phenylacetyl, phenoxyacetyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, 2-iodoethoxycarbonyl, carbobenzoxy-carbonyl, 4-methoxybenzyloxycarbonyl, 9fluorenylmethoxycarbonyl or 4-methoxy-2,3,6-trimethyl-phenylsulfonyl,R2, R3and R4are H and X is 0, is hydrogenated with the aid of an enantiomerically enriched catalyst,b) in that, from the enantiomerically enriched mixture of the (R) and (S) compounds of the formula I thus obtained, in whichR1is acyl having 1-6 carbon atoms, -CO-R5, phenylacetyl, phenoxyacetyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, 2-iodoethoxycarbonyl, carbobenzoxy-carbonyl, 4-methoxybenzyloxycarbonyl, 9fluorenylmethoxycarbonyl or 4-methoxy-2,3,6-trimethyl-phenylsulfonyl,R2, R3and R4are H and X is 0, the enantiomerically pure (R) compound of the formulaI , in whichR1is acyl having 1-6 carbon atoms., -CO-R5, phenylacetyl, phenoxyacetyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, 2-iodoethoxycarbonyl, carbobenzoxy-carbonyl, 4-methoxybenzyloxycarbonyl, 9fluorenylmethoxycarbonyl or 4-methoxy-2,3,6-trimethyl-phenylsulfonyl,R2, R3and R4are H and X is 0, is obtained by crystallization, in thatc) the enantiomerically pure (R) compound of the formula I , in whichPI 99005404R1is acyl having 1-6 carbon atoms, -CO-R5, phenylacetyl, phenoxyacetyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, 2-iodoethoxycarbonyl, carbobenzoxy-carbonyl, 4-methoxybenzyloxycarbonyl, 9fluorenylmethoxycarbonyl or 4-methoxy-2,3,6-trimethyl-phenylsulfonyl, R2, R3and R4are H and X is 0, is then reduced in the customary manner, in thatd) the radical R1in whichR1is acyl having 1-6 carbon atoms, -CO-R5, phenylacetyl, phenoxyacetyl, methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, 2-iodoethoxycarbonyl, carbobenzoxy-carbonyl, 4-methoxybenzyloxycarbonyl, 9fluorenylmethoxycarbonyl or 4-methoxy-2,3,6-trimethyl-phenylsulfonyl,R2, R3and R4are H and X is H,H, is removed from the (R) compound of the formula I thus obtained, in thate) the (R)-(chroman-2-ylmethyl) amine thus obtained is converted into its acid addition salt and this is reacted in a known manner to give (R) -2- [5- (4fluorophenyl) -3-pyridylmethylaminomethyl]chroman and, if appropriate, converted into its acid addition salt,PI 99005404 where the recovery of the (R) enantiomer can also be carried out by crystallization from the enantiomerically enriched (R,S) mixture after stage c) or after stage d).The invention furthermore relates to the use of the compounds of the formula I as intermediates for the synthesis of medicaments which show actions on the central nervous system.Above and below, all temperatures are indicated in °C. In the following examples, customary working up means: if necessary, water is added, the mixture is adjusted, if necessary, depending on the constitution of the final product, to a pH of between 2 and 10 and extracted with ethyl acetate or dichloromethane, the organic phase is separated off, dried over sodium sulfate and evaporated, and the residue is purified by chromatography on silica gel and / or by crystallization. Rfvalues on silica gel.ExamplesExperimental data (complex preparation, hydrogenation, analytical methods):All reactions were carried out under inert conditions (i.e. anhydrous and oxygen-free reaction conditions).1. Preparation of the catalyst / substrate solution:PI 99005404I. 1. Example :II. 2 mg of RhtCOD / jOTf (rhodium-cyclooctadiene triflate) were dissolved in 5 ml of methanol and cooled to 0°C. A cooled solution of 1 . 1 eq of bisphosphane (e.g. 12.6 mg of (R,R)-Skewphos) in 5 ml of methanol was then added. After stirring at room temperature for 10 min, the complex solution was treated with the substrate solution consisting of 110 mg of (2acetylaminomethyl)chromen-4-one in 10 ml of methanol.1.2. Example :51.4 mg of [Rh(COD)Cl]2were dissolved in 4 ml of the solvent mixture toluene / methanol 5:1 and treated with a solution consisting of 5 ml of toluene, 1 ml of methanol and 1.1 eq of bisphosphane (e.g. 130.6 mg of (R)-BINAP). 1 ml of this catalyst complex solution was added to 510.8 mg of (2-acetylaminomethyl)chromen-4one, dissolved in 15 ml of toluene and 3 ml of methanol .2. Enantioselective hydrogenationThe catalyst / substrate solution to be hydrogenated was filled into an autoclave in a countercurrent of protective gas. The protective gas atmosphere was replaced by flushing several times with hydrogen (0.1-0.5 MPa [1-5 bar] H2atmosphere). The batches analogous to 1.1. reacted even at room temperature and 5 bar of hydrogen. The catalysts analogous to 1.2. afforded the best results at 50 °C and 8 MPa (80 bar) of hydrogen. As a rule, the hydrogenation was terminated after 15 hours.3. Sampling and analytical methodsA sample was taken in a gas. The complex was chromatography on silica before the determination countercurrent of protective separated off by column gel (eluent: ethyl acetate) of the enantiomeric excesses.PI 99005404The enantiomeric excess of the hydrogenation product was determined on the chiral HPLC phase:Column: Daicel Chiralcel OJ (I.D. x length / mm:4.6x250)Eluent: n-hexane: i-propanol = 9:1Flow: O.S ml / min (1.8 MPa [18 bar], 28 °C)Detection: UV 250 nmRetention: Rt(j?) = 27 mm; RC(S) = 29 minThe concentration of the crude hydrogenation solution led to the precipitation of the product. An increase in the enantiomeric excess was detected by means of fractional crystallization.4. Further reductionAfter complete conversion was detected, the reduction the <eto group was carried out by means of 20 palladium-carbon as a one-pot process. The crude ketone solution resulting from the homogeneous hydrogenation was treated with 10% by weight water-moist palladiumcarbon (e.g. 100 mg of water-moist Pd / C to 1 g of (2-acetylaminomethyl)chromen-4-one) and 1 ml of glacial 25 acetic acid. Hydrogenation was carried out at a hydrogen pressure of 0.7 MPa (7 bar) and 50 °C for 14 h.5. Work-up and analytical methodsTheThe was pfi11adium-carbon was removed bv filtration, enantiomeric excess of the hydrogenation determined on a chiral HPLC phase:productColumn : Daicel Chiralcel OJ (I.D. x length / mm: 35 4.6 x 2 5 0) Eluent : n-hexane: i-propanol = 9:1 Flow: 0.8 ml / min (1.8 MPa [18 bar], 28 °C) Detection : UV 250 nm Retention : Rc (R) = 25 min; RC(S) = 27 rninrl 99005404During the reduction with palladium-carbon, the enantiomeric excess remained unchanged.The concentration of the crude hydrogenation solution 5 led to the precipitation of the product. An increase in the enantiomeric excess was detected by means of fractional crystallization.PI 99005404Enantioselectivities o,f the homogeneous hydrogenation:0Elab No. Complex:metal anion ligand (addition) Solvent Pressure % ee 1. 18 Rh-OT f-(AA)-EtDuphos CH2C12 I 55 S 2. 13 RJa-OTf-ZA. J?)-EtDupbos THE 1 44 S 14 Rh-OT Ε(Λ,7?)-ΕιΕ>υρΕοε MeOH 1 64 S 4. 15 Rh-OT f-(A. 7?)-EtDuphos EE 1 33 S 5. 6 RJb-OTf-(7?,J?)-EtDupbos / PrOH 1 20 S 6. 23a Rh-OTf-(7?,7?)-EtDuphos MeOH 1 34 S 7. 23b R.b-OTf-(A7?)-EtDupbos MeOH 1 36 S 8. 23c Rb-OTf-(7?,J?)-EtDuphos MeOH 5 45 S 9. 23d R.h-OT f-(7?.A)-ElDuphos MeOH 5 31 S 10. 12 Ru-Cl2-(J?)-BINAP / PrOH 5 50 S (AgOOCCFj) 11. 19 Rh-ClO4-(S,S)-Chiiaphos iPrOH 1 - 12. 20 Rh-OTf-(S,5>DIOP THF 1 rac. 13. 20 Rh-OTf-(S,S)-DIOP THF 3 8 R 14. 21 Rh-OT f-(J?.7?)-Skewpbos THF 1 - 15. 22b Rh-OTf-(S,S)-BPPM MeOH 1 7 S Ιό. 24a Rh-OTf-{A.S)-BPPFOH MeOH 1 54 R 17. 24b Rh-OTf-(A,^-BPPFOH MeOH 1 54 R 18. 24c Rh-OTf-(J?,S)-BPPFOH MeOH 5 63 R 19. 25a Rb-OTf-(2?)-BrNAB MeOH 1 1 R 20. 25b Rh-OT f-(J?)-BINAP MeOH rac. 21. 26a Rh-OT f-(S,S)-N orpbos MeOH 1 42 R 2° 26b Rh-OTf-GS,S)-Norphos MeOH 60 R 23 26c R_b-OTf-(S.5)-Norpbos LPrOH 5 12 R 24. 26d Rh-OT f-(S.S)-Norphos THF 5 3 R 25. 27a Rh-OTf-(S.S)-NoTphos MeOH 8 64 R 26. 27b Rdi-Cl-(S,S)-Norphos MeOH 8 40 R 27. 27c Rh-OT f-(S,S)-Norphos MeOH 30 65 R 28. 27d Rh-OT f-(5.5)-Norphos MeOH 60 64 R 29. 28a Rh-OT HA.A)-EtDUPhos MeOH 10 16 S 30. 28b Rh-OTf-(0)-EtDUPhos MeOH 30 28 S 31. 29a Rb-OTf-<A,S)-BPPFOH MeOH 10 55 R 32. 29b Rb-OTf-(A,5)-BPPFOH MeOH 30 56 R 33. 37 Rh-ClO4-(S,5)-Chiiaphos MeOH 10 30 R 34. 38 Rh-OTf-(S.S)-D10P MeOH 10 rac. 35. 39 Rh-OTf-(A.A)-Skev.-pbos .MeOH 10 46 S 36. 40 Rh-OTf-(5.S)-BPP.M MeOH 10 9 S 37. 41 lr-Cl-(S,S)-D10P MeOH 10 8 R 38. 42 Ir-Cl-(S,S)-DIOP CH,C12 10 7 S0. 43 Ir-Cl-(S,5)-DIOP (- 1) MeOH 10 - 1. 44 Lr-CHS,S)-DIOP. (+ I) MeOH 30 - 2. 45 Lr-Cl-(S.S)-DIOP (- 1 MeOH 10 - 5 +CH3COOH) 3. 46 Ir-0Tf-(5.5)-D10P MeOH 10 HR 4. 47 lr-OTf-(S,5>DIOP (+ I) MeOH 10 39 R 5. 49 Rh-OT f-^Jl-Norptios MeOH 10, RT 57 R 6. 50 Rh-OT f-(S,5j-Norphos MeOH 10,50°C 60 R 7. 52 Rh-BMA,S)-PFctB MeOH 10, 50°C 33 S 10 8. 54 Rb-Cl-(7?;-BINAP TokMeOH 5:1 80, 50°C 9IS 9. 59 Rh-Cl-(5,5)-Norpbos TokMeOH 5:1 80, 50°C 19 R 10. 62 crude 59 / / Pd / C TokMeOH 5:1 7, 50°C 18 RPI 99005404
Claims
1. Chroman derivatives of the formula I CLAIMS in which R1 is acyl having 1-6 carbon atoms, -CO-R5, phenylacetyl, phenoxyacetyl, 5 methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, tert-butoxycarbonyl, 2-iodoethoxycarbonyl, carbobenzoxy-carbonyl, 4-methoxybenzyloxycarbonyl, 9fluorenylmethoxycarbonyl or 4-methoxy-2,3,6-trimethyl-phenylsulfonyl, R2 is H or alkyl having 1-6 carbon atoms, R3 and R4 are each, independently of one another, H, alkyl having 1-6 carbon atoms, CN, Hal or COOR2, R5 is phenyl which is unsubstituted or 10 monosubstituted or disubstituted by alkyl having 1-6 carbon atoms, OR2 or Hal, X is H,H or O, Hal is F, Cl, Br or I, and salts thereof, where N-(chroman-2ylmethyl)cyclopropanecarboxamide is excluded.
2. Enantiomers of the compounds of the formula I according to Claim 1.
3. Compounds of the formula I according to Claim 1 15 a) N-(4-oxochroman-2-ylmethyl)acetamide; b) N-(chroman-2-ylmethyl)acetamide; c) (S)-N-(4-oxochroman-2-ylmethyl)acetamide; d) (R)-N-(4-oxochroman-2-ylmethyl)acetamide; e) (S)-N-(chroman-2-ylmethyl)acetamide; 20 f) (R)-N-(chroman-2-ylmethyl)acetamide; and salts thereof. PI 990054044. Process for the preparation of chroman derivatives of the formula I according to Claim 1 and salts thereof, in which X is O, characterised in that a compound of the formula II JI in which R1, R\ R3 and R4 are as defined in Claim 1, and X is 0, is hydrogenated with 5 the aid of an enantiomerically enriched catalyst.
5. Process for the preparation of chroman derivatives of the formula I according to Claim 1 and salts thereof, in which X is H,H, characterised in that a compound of the formula II in which R1, R\ R3 and R4 are as defined in Claim 1, and X is 0, is hydrogenated with the aid of an enantiomerically enriched catalyst and subsequently reduced in a conventional manner. PI 990054046. Process for the preparation of chroman derivatives of the formula I according to Claim 4 or 5, characterised in that the enantiomerically enriched catalyst is a transitionmetal complex.
7. Process for the preparation of chroman derivatives of the formula I according to 5 Claim 4, 5 or 6, characterised in that the catalyst is a transition-metal complex containing a metal selected from the group consisting of rhodium, iridium, ruthenium and palladium.
8. Process for the preparation of chroman derivatives of the formula I according to Claim 4, 5, 6 or 7, characterised in that the catalyst is a transition-metal complex in IQ which the transition metal is complexed to a chiral diphosphine ligand.
9. Use of the compounds of the formula I according to Claim 1 as intermediates in the synthesis of medicaments.
10. Use of the compounds of the formula I according to Claim 1 as intermediates in the synthesis of medicaments which exhibit actions on the central nervous system.15 11 · Use of the compounds of the formula I according to Claim 1 in the synthesis of (R)-2-[5-(4-fluorophenyl)-3-pyridyl-methylaminomethyl]-chroman and salts thereof, characterised in that a) a compound of the formula II R2 I R4 in which R1 is as defined in Claim 1, R2, R3 and R4 are H and X is 0, is hydrogenated20 with the aid of an enantiomerically enriched catalyst, b) in that the enantiomerically pure » (R) compound of the formula I in which R1 is as defined in Claim 1, R2, R3 and R4 are H * and X is O, is isolated from the resultant enantiomerically enriched mixture of the (R) ’ and (S) compounds of the formula I in which R1 is as defined in Claim 1, R2, R3 and R4 are H and X is 0, by crystallisation, in that c) the enantiomerically pure (R) compound of 5 the formula I in which R1 is as defined in Claim 1, R2, R3 and R4 are H and X is 0, is subsequently reduced in a conventional manner, in that d) the radical R1 is cleaved off from the resultant (R) compound of the formula I in which R1 is as defined in Claim 1, R2, R3 and R4 are H and X is H,H, in that e) the resultant (R)-(chroman-2ylmethyl)amine is converted into its acid-addition salt, and the latter is converted in a 10 known maimer into (R)-2-[5-(4-fluorophenyl)-3-pyridylmethylaininomethyl]chiOman < and, if desired, converted into its acid-addition salt, where the isolation of the (R) enantiomer from the enantiomerically enriched (R,S) mixture by crystallisation can also be earned out after step c) or after step d).
